ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 924-930

  Nikolac, Nora ^a   Simundic, Ana Maria ^a   Saracevic, Andrea ^a   Katalinic, Darko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA; TRIACYLGLYCEROL;

ABCC8 GENE; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; EXON; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; EXONS; FEMALE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES;

EID: 84865674893     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0337     Document Type: Article

References (32)

1. Aguilar-Bryan L, Bryan J (1999) Molecular biology of adenosine triphosphatesensitive potassium channels. Endocr Rev 20:101-135.
2. Aittoniemi J, Fotinou C, Craig TJ, et al. (2009) SUR-1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos Trans R Soc Lond B Biol Sci 364:257-267.
3. American Diabetes Association (2010) Standards of Medical Care in Diabetes-2010. Diabetes Care 33 (Suppl 1): S11-S61.
4. Aquilante CL (2010) Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 8:359-372.
5. Cook DL, Satin LS, Ashford MLJ, Hales CN (1988) ATP sensitive K+ channels in pancreatic b-cells. Diabetes 37:495-498.
6. Dworacka M, Winiarska H, Jagodziński PP (2007) Impact of the sulfonylurea receptor 1 (SUR1) exon 16-3c/t polymorphism on acute hyperglycaemia in type 2 diabetic patients. Diabetes Res Clin Pract 77:258-262.
7. Flanagan SE, Clauin S, Bellanné-Chantelot C, et al. (2009) Update of mutations in the genes encoding the pancreatic beta-cell K (ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 30:170-180.
8. Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8:657-662.
9. Goksel DL, Fischbach K, Duggirala R, et al. (1998) Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum Genet 103:280-285.
10. Grundy SM, Cleeman JI, Merz CN, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44:720-732.
11. Hamming KS, Soliman D, Matemisz LC, et al. (2009) Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K (+) channel. Diabetes 58:2419-2424.
12. Hanefeld M (2007) Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract 61:20-27.
13. Hart LM, de Knijff P, Dekker JM, et al. (1999) Variants in the sulphonylurea receptor gene: association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians. Diabetologia 42:617-620.
14. Holman RR, Paul SK, Bethel MA, et al. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589.
15. Kifagi C, Makni K, Boudawara M, et al. (2011) Association of genetic variations in TCF7L2, SLC30A8, HHEX, LOC387761, and EXT2 with Type 2 diabetes mellitus in Tunisia. Genet Test Mol Biomarkers 15:399-405.
16. Krugluger W, Festa A, Shnawa N, et al. (2000) A serine/alanine polymorphism in the nucleotide-binding fold-2 of the sulphonylurea receptor-1 (S1369A) is associated with enhanced glucose-induced insulin secretion during pregnancy. J Inherit Metab Dis 23:705-712.
17. Lippi G, Favaloro EJ (2009) The missing link between genotype, phenotype and clinics. Biochem Med 19:137-145.
18. Marusteri M, Bacarea V (2010) Comparing groups for statistical differences: how to choose the right statistical test? Biochem Med 20:15-32.
19. McHugh ML (2011) Multiple comparison analysis testing in ANOVA. Biochem Med 21:203-209.
20. Meirhaeghe A, Helbecque N, Cottel D, et al. (2001) Impact of sulfonylurea receptor 1 genetic variability on non-insulindependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet 101:4-8.
21. Nichols CG, Koster JC (2002) Diabetes and insulin secretion: whither KATP? Am J Physiol Endocrinol Metab 283:E403-E412.
22. Nikolac N, Simundic AM, Katalinic D, et al. (2009) Metabolic Control in Type 2 Diabetes Is Associated with Sulfonylurea Receptor-1 (SUR-1) but Not with KCNJ11 Polymorphisms. Arch Med Res 40:387-392.
23. Qiao Q, Nyamdorj R (2010) Is the association of type II diabetes with waist circumference or waist-to-hip ratio stronger than that with body mass index? Eur J Clin Nutr 64:30-34.
24. Reis AF, Velho G (2002) Sulfonylurea receptor-1 (SUR-1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus. Diabetes Metab 28:14-19.
25. Reis FA, Ye WZ, Dubois-Laforgue D, et al. (2000) Association of a variant in exon 31 of the sulfonylurea receptor 1 (SUR-1) gene with type 2 diabetes mellitus in French Caucasians. Hum Genet 107:138-144.
26. Sacks DB, Bruns DE, Goldstein DE, et al. (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48:436-472.
27. Stratton IM, Adler AI, Neil HA, et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412.
28. Turner RC, Holman RR, Cull CA, et al. (1998) Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853.
29. Viberti G, Kahn SE, Greene DA, et al. (2002) A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25:1737-1743.
30. World health organization (2006) Definition and diagnosis of diabetes. Available at: www.who.int/diabetes/publications/ Definition%20and%20diagnosis%20of%20diabetes-new.pdf. Accessed February 14, 2011.
31. Zalesin KC, Franklin BA, Miller WM, et al. (2011) Impact of obesity on cardiovascular disease. Med Clin North Am 95:919-937.
32. Zhang H, Liu X, Kuang H, et al. (2007) Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract 77:58-61.